GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zogenix Inc (NAS:ZGNX) » Definitions » Total Current Liabilities

Zogenix (Zogenix) Total Current Liabilities : $97.69 Mil (As of Dec. 2021)


View and export this data going back to 2010. Start your Free Trial

What is Zogenix Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Zogenix's total current liabilities for the quarter that ended in Dec. 2021 was $97.69


Zogenix Total Current Liabilities Historical Data

The historical data trend for Zogenix's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zogenix Total Current Liabilities Chart

Zogenix Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.98 58.38 95.39 82.72 97.69

Zogenix Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.72 58.53 69.34 78.43 97.69

Zogenix Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Zogenix's Total Current Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=61.012+1.694
+Other Current Liabilities+Current Deferred Liabilities
=29.899+5.089
=97.69

Zogenix's Total Current Liabilities for the quarter that ended in Dec. 2021 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=61.012+1.694
+Other Current Liabilities+Current Deferred Liabilities
=29.899+5.089
=97.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Zogenix Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Zogenix's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Zogenix (Zogenix) Business Description

Industry
Traded in Other Exchanges
N/A
Address
5959 Horton Street, Suite 500, Emeryville, CA, USA, 94608
Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.
Executives
Erle T Mast director C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Cam L Garner director PO BOX 675866, RANCHO SANTE FE CA 92067
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Denelle J Waynick director C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary E. Stutts director C/O ZOGENIX, INC. 5959 HORTON STREET EMERYVILLE CA 94608
Ashish M Sagrolikar officer: EVP & CHIEF COMMERCIAL OFFICER C/O ZOGENIX, INC. 5858 HORTON STREET, #455 EMERYVILLE CA 94608
Gail M Farfel officer: EVP/Chief Development Officer 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Bradley S. Galer officer: EVP/Chief Medical Officer C/O ZOGENIX, INC. 12400 HIGH BLUFF DR., SUITE 650 SAN DIEGO CA 92130
Stephen J Farr director, officer: President and CEO [email protected] EMERYVILLE CA 94608
Mark C Wiggins director 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Louis C Bock director C/O BANKAMERICA VENTURES, 950 TOWER LANE STE 700, FOSTER CITY CA 94404
James B Breitmeyer director
Shawnte Mitchell officer: EVP, GC and Secretary 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael P Smith officer: EVP, CFO, Treasurer & Sec. 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5

Zogenix (Zogenix) Headlines